Given that the MK-NCL axis has been identified as a significant L-R pair in both immunosuppressive NPC and hyperinflammatory COVID-19, the pharmacological targeting of MK-NCL signaling may be a promising approach to reshape the local immune microenvironment to be more therapy-permissive. Here, MDK is linked to COVID-19.